81 filings
Page 3 of 5
6-K
vwri6ieg 3d
11 May 23
Current report (foreign)
7:00am
6-K
npiecw
3 May 23
Current report (foreign)
1:25pm
6-K
h7q20
3 May 23
Result of General Meeting
9:50am
6-K
0ki8majw7ev
3 May 23
Current report (foreign)
7:00am
6-K
9oqppphe 8ruyrguemjd
2 May 23
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
7:00am
6-K
772q4rv
25 Apr 23
Current report (foreign)
7:00am
6-K
pz8zb k7ywjhbcst
5 Apr 23
Current report (foreign)
7:00am
6-K
l4ptk x2ax0r
4 Apr 23
Current report (foreign)
7:00am
6-K
0snsr
30 Mar 23
Director Acquires Shares
7:00am
6-K
mj3vcxm8omwu3symbui
29 Mar 23
Director acquires shares
7:00am
6-K
18lnwix
24 Mar 23
Current report (foreign)
7:00am
6-K
qmso paoprvg8xpxul9
16 Mar 23
Current report (foreign)
7:00am
6-K
5xwnfzy9pa jrhy6e
15 Mar 23
Current report (foreign)
4:15pm
6-K
su5263orlbxcyl5g
15 Mar 23
Current report (foreign)
7:00am
6-K
6l76ktn76c3ys3
14 Mar 23
Current report (foreign)
7:00am
6-K
uloisil a9evr4zeut
13 Mar 23
Current report (foreign)
4:15pm
6-K
47hos6x04eedkmi
28 Feb 23
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
7:00am
6-K
jnhqo
23 Feb 23
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board
7:00am
6-K
4qwzh6xdu8u7qq
21 Feb 23
Report of Foreign Private Issuer
7:00am
6-K
m8b62d
14 Feb 23
Report of Foreign Private Issuer
7:00am